User menu

Biological and clinical developments in melanoma vaccines

Bibliographic reference Marchand, Maurice ; Brichard, V. ; van Baren, Nicolas ; Coulie, Pierre. Biological and clinical developments in melanoma vaccines. In: Expert Opinion on Biological Therapy, Vol. 1, no. 3, p. 497-510 (2001)
Permanent URL
  1. BURNET FM, Transplant. Rev., 7, 3 (1971)
  2. Marincola Francesco M., Jaffee Elizabeth M., Hicklin Daniel J., Ferrone Soldano, Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance, Advances in Immunology (1999) ISBN:9780120224746 p.181-273, 10.1016/s0065-2776(08)60911-6
  3. Van Pel A., Boon T., Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis., 10.1073/pnas.79.15.4718
  4. KIRKWOOD JM, Clin. Oncol., 18, 2444 (2000)
  5. Lanzavecchia A., Dynamics of T Lymphocyte Responses: Intermediates, Effectors, and Memory Cells, 10.1126/science.290.5489.92
  6. Inaba K., Dendritic cells pulsed with protein antigens in vitro can prime antigen- specific, MHC-restricted T cells in situ [published erratum appears in J Exp Med 1990 Oct 1;172(4):1275], 10.1084/jem.172.2.631
  7. Schuler G., Steinman R.M., Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors, 10.1084/jem.186.8.1183
  8. Ossendorp Ferry, Mengedé Erica, Camps Marcel, Filius Rian, Melief Cornelis J.M., Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors, 10.1084/jem.187.5.693
  9. Kim Christina J., Prevett Tracy, Cormie Janice, Overwijk Willem, Roden Matthew, Restifo Nicholas P., Rosenberg Steven A., Marincola Francesco M., Dendritic Cells Infected with PoxvIn Vitro iruses Encoding MART-1/ Melan A Sensitize T Lymphocytes In Vitro : , 10.1097/00002371-199707000-00004
  10. BUTTERFIELD LH, j Immunol, 161, 5607 (1998)
  11. CHAUX P, J. Immunol., 163, 2928 (1999)
  12. Russo V., Tanzarella S., Dalerba P., Rigatti D., Rovere P., Villa A., Bordignon C., Traversari C., Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response, 10.1073/pnas.040540197
  13. Nestle Frank O., Alijagic Selma, Gilliet Michel, Sun Yuansheng, Grabbe Stephan, Dummer Reinhard, Burg Günter, Schadendorf Dirk, Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells, 10.1038/nm0398-328
  14. Chaux Pascal, Vantomme Valérie, Stroobant Vincent, Thielemans Kris, Corthals Jurgen, Luiten Rosalie, Eggermont Alexander M.M., Boon Thierry, van der Bruggen Pierre, Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+T Lymphocytes, 10.1084/jem.189.5.767
  15. Dhodapkar Madhav V., Steinman Ralph M., Sapp Mark, Desai Hema, Fossella Coraleen, Krasovsky Joseph, Donahoe Sean M., Dunbar P. Rod, Cerundolo Vincenzo, Nixon Douglas F., Bhardwaj Nina, Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells, 10.1172/jci6909
  16. YEE C, J. Immunol, 157, 4079 (1996)
  17. YEE C, j Immunol., 162, 2227 (1999)
  18. VALMORI D, Cancer Res., 59, 2167 (1999)
  19. Aichele P., Kyburz D., Ohashi P. S., Odermatt B., Zinkernagel R. M., Hengartner H., Pircher H., Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model., 10.1073/pnas.91.2.444
  20. BERD D, J. Clin. Oncol., 15, 2359 (1997)
  21. Dunnion D. J., Cywinski A. L., Tucker V. C., Murray A. K., Rickinson A. B., Coulie P., Browning M. J., Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro, 10.1046/j.1365-2567.1999.00912.x
  22. Müller Gerhard A., Ringert Rolf-Hermann, Kugler Alexander, Stuhler Gernot, Walden Peter, Zöller Gerhard, Zobywalski Anke, Brossart Peter, Trefzer Uwe, Ullrich Silke, Müller Claudia A., Becker Volker, Gross Andreas J., Hemmerlein Bernhard, Kanz Lothar, 10.1038/73193
  23. Tamura Y., Immunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations, 10.1126/science.278.5335.117
  24. Chandawarkar Rajiv Y., Wagh Mihir S., Srivastava Pramod K., The Dual Nature of Specific Immunological Activity of Tumor-derived gp96 Preparations, 10.1084/jem.189.9.1437
  25. MORTON DONALD L., FOSHAG LELAND J., HOON DAVE S.B., NIZZE J. ANNE, WANEK LESLIE A., CHANG CINDY, DAVTYAN DAVID G., GUPTA RISHAB K., ELASHOFF ROBERT, IRIE REIKO F., Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine : , 10.1097/00000658-199210000-00010
  26. Hsueh Eddy C., Nathanson Larry, Foshag Leland J., Essner Richard, Nizze J. Anne, Stern Stacey L., Morton Donald L., Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases, 10.1002/(sici)1097-0142(19990515)85:10<2160::aid-cncr10>;2-0
  27. HSUEH EC, J. Clin. Oncol, 16, 2913 (1998)
  28. Bystryn J.-C., Clinical Activity of a Polyvalent Melanoma Antigen Vaccine, Recent Results in Cancer Research (1995) ISBN:9783642787737 p.337-348, 10.1007/978-3-642-78771-3_26
  29. HERSEY P, COATES A, MCCARTHY W: Vaccinia melanoma cell lysates (VMCL) in immunotherapy of stage Ilb and III melanoma. 3r1 International Conference "The adjuvant therapy of malignant melanoma", London, UK (1999).
  30. Boon Thierry, Cerottini Jean-Charles, Van den Eynde Benoit, van der Bruggen Pierre, Van Pel Aline, Tumor Antigens Recognized by T Lymphocytes, 10.1146/annurev.iy.12.040194.002005
  31. RIVOLTINI L, J. Immunol, 154, 2257 (1995)
  32. VAN DER BRUGGEN P, TRAVERSARI C,, Science, 1991, 1643– (1647)
  33. Cox A., Skipper J, Chen Y, Henderson R., Darrow T., Shabanowitz J, Engelhard V., Hunt D., Slingluff C., Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines, 10.1126/science.7513441
  34. Van den Eynde Benoît J, van der Bruggen Pierre, T cell defined tumor antigens, 10.1016/s0952-7915(97)80050-7
  35. Lucas Sophie, De Plaen Etienne, Boon Thierry, MAGE-B5, MAGE-B6, MAGE-C2, andMAGE-C3: four new members of theMAGE family with tumor-specific expression, 10.1002/1097-0215(20000701)87:1<55::aid-ijc8>;2-j
  36. De Smet Charles, Lurquin Christophe, Lethé Bernard, Martelange Valérie, Boon Thierry, DNA Methylation Is the Primary Silencing Mechanism for a Set of Germ Line- and Tumor-Specific Genes with a CpG-Rich Promoter, 10.1128/mcb.19.11.7327
  37. De Plaen Etienne, Traversari Catia, Gaforio José J., Szikora Jean-Pierre, De Smet Charles, Brasseur Francis, van der Bruggen Pierre, Lethé Bernard, Lurquin Christophe, Chomez Patrick, De Backer Olivier, Boon Thierry, Arden Karen, Cavenee Webster, Brasseur Robert, Structure, chromosomal localization, and expression of 12 genes of the MAGE family, 10.1007/bf01246677
  38. TANZARELLA S, Cancer Res., 59, 2668 (1999)
  39. SCHULTZ ES, Cancer Res, 60, 6272 (2000)
  40. Schultz E.S., Zhang Y., Knowles R., Tine J., Traversari C., Boon T., van der Bruggen P., A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes, 10.1034/j.1399-0039.2001.057002103.x
  41. Luiten R.M., Demotte N., Tine J., van der Bruggen P., A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules, 10.1034/j.1399-0039.2000.560110.x
  42. Chen Y.-T., Scanlan M. J., Sahin U., Tureci O., Gure A. O., Tsang S., Williamson B., Stockert E., Pfreundschuh M., Old L. J., A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening, 10.1073/pnas.94.5.1914
  43. Aarnoudse Corlien A., van den Doel Petra B., Heemskerk Bianca, Schrier Peter I., Interleukin-2-induced, melanoma-specific T cells recognize camel, an unexpected translation product ofLAGE-1, 10.1002/(sici)1097-0215(19990730)82:3<442::aid-ijc19>;2-z
  44. MARTELANGE V, Cancer Res., 60, 3848 (2000)
  45. Guilloux Y., A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N- acetylglucosaminyltransferase V gene, 10.1084/jem.183.3.1173
  46. Lupetti Raffaella, Pisarra Patrizia, Verrecchia Alessandro, Farina Cinthia, Nicolini Gabriella, Anichini Andrea, Bordignon Claudio, Sensi Marialuisa, Parmiani Giorgio, Traversari Catia, Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage, 10.1084/jem.188.6.1005
  47. Topalian S. L., Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes, 10.1084/jem.183.5.1965
  48. KOBAYASHI H, Cancer Res, 58, 296 (1998)
  49. Zarour H. M., Kirkwood J. M., Kierstead L. S., Herr W., Brusic V., Slingluff C. L., Sidney J., Sette A., Storkus W. J., Melan-A/MART-151-73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells, 10.1073/pnas.97.1.400
  50. Pittet Mikaël J., Valmori Danila, Dunbar P. Rod, Speiser Daniel E., Liénard Danielle, Lejeune Ferdy, Fleischhauer Katharina, Cerundolo Vincenzo, Cerottini Jean-Charles, Romero Pedro, High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals, 10.1084/jem.190.5.705
  51. LIVINGSTON PO, J. Clin. Oncol., 12, 1036 (1994)
  52. Jäger Elke, Chen Yao-Tseng, Drijfhout Jan W., Karbach Julia, Ringhoffer Mark, Jäger Dirk, Arand Michael, Wada Hisashi, Noguchi Yuji, Stockert Elisabeth, Old Lloyd J., Knuth Alexander, Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes, 10.1084/jem.187.2.265
  53. Marchand Marie, van Baren Nicolas, Weynants Patrick, Brichard Vincent, Dr�no Brigitte, Tessier Marie-H�l�ne, Rankin Elaine, Parmiani Giorgio, Arienti Flavio, Humblet Yves, Bourlond Andr�, Vanwijck Romain, Li�nard Danielle, Beauduin Marc, Dietrich Pierre-Yves, Russo Vincenzo, Kerger Joseph, Masucci Giuseppe, J�ger Elke, De Greve Jacques, Atzpodien Jens, Brasseur Francis, Coulie Pierre G., van der Bruggen Pierre, Boon Thierry, Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1, 10.1002/(sici)1097-0215(19990118)80:2<219::aid-ijc10>;2-s
  54. WEBER JS, A-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma. J. Immunother., 22, 431 (1999)
  55. Jäger Elke, Ringhoffer Mark, Karbach Julia, Arand Michael, Oesch Franz, Knuth Alexander, Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variantsin vivo, 10.1002/(sici)1097-0215(19960516)66:4<470::aid-ijc10>;2-c
  56. J�ger Elke, Ringhoffer Mark, Dienes Hans Peter, Arand Michael, Karbach Julia, J�ger Dirk, Ilsemann Christiane, Hagedorn Manfred, Oesch Franz, Knuth Alexander, Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptidesin vivo, 10.1002/(sici)1097-0215(19960703)67:1<54::aid-ijc11>;2-c
  57. SALGALLER ML, Cancer Res, 56, 4749 (1996)
  58. CORMIER JN, Cancer J. Sci. Am., 3, 37 (1997)
  59. ROSENBERG SA, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med., 4, 321 (1998)
  60. ROSENBERG SA, j immunoi, 163, 1690 (1999)
  61. WANG F, Clin. Cancer Res., 5, 2756 (1999)
  62. Scheibenbogen Carmen, Schmittel Alexander, Keilholz Ulrich, Allgäuer Thomas, Hofmann Udo, Max Regina, Thiel Eckhard, Schadendorf Dirk, Phase 2 Trial of Vaccination With Tyrosinase Peptides and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma : , 10.1097/00002371-200003000-00012
  63. Lewis Jonathan J., Janetzki Sylvia, Schaed Susanne, Panageas Katherine S., Wang Siqun, Williams Linda, Meyers Michael, Butterworth Leah, Livingston Philip O., Chapman Paul B., Houghton Alan N., Evaluation of CD8+ T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide, 10.1002/1097-0215(20000801)87:3<391::aid-ijc13>;2-k
  64. Rosenberg S. A., Zhai Y., Yang J. C., Schwartzentruber D. J., Hwu P., Marincola F. M., Topalian S. L., Restifo N. P., Seipp C. A., Einhorn J. H., White D. E., Roberts B., Immunizing Patients With Metastatic Melanoma Using Recombinant Adenoviruses Encoding MART-1 or gp100 Melanoma Antigens, 10.1093/jnci/90.24.1894
  65. Thurner Beatrice, Haendle Ina, Röder Claudia, Dieckmann Detlef, Keikavoussi Petra, Jonuleit Helmut, Bender Armin, Maczek Christian, Schreiner Doris, von den Driesch Peter, Bröcker Eva B., Steinman Ralph M., Enk Alexander, Kämpgen Eckhart, Schuler Gerold, Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma, 10.1084/jem.190.11.1669
  66. Mukherji B., Chakraborty N. G., Yamasaki S., Okino T., Yamase H., Sporn J. R., Kurtzman S. K., Ergin M. T., Ozols J., Meehan J., Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells., 10.1073/pnas.92.17.8078
  67. HU X, Cancer Res, 56, 2479 (1996)
  68. Yee Cassian, Thompson John A., Roche Patrick, Byrd David R., Lee Peter P., Piepkorn Michael, Kenyon Karla, Davis Mark M., Riddell Stanley R., Greenberg Philip D., Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma : Direct Evidence of T Cell–Mediated Vitiligo, 10.1084/jem.192.11.1637
  69. Zitvogel Laurence, Regnault Armelle, Lozier Anne, Wolfers Joseph, Flament Caroline, Tenza Danielle, Ricciardi-Castagnoli Paola, Raposo Graça, Amigorena Sebastian, Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes, 10.1038/nm0598-594
  70. Fallarino Francesca, Uyttenhove Catherine, Boon Thierry, Gajewski Thomas F., Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12, 10.1002/(sici)1097-0215(19990118)80:2<324::aid-ijc25>;2-d
  71. Altman J. D., Moss P. A. H., Goulder P. J. R., Barouch D. H., McHeyzer-Williams M. G., Bell J. I., McMichael A. J., Davis M. M., Phenotypic Analysis of Antigen-Specific T Lymphocytes, 10.1126/science.274.5284.94
  72. Dunbar P.R., Ogg G.S., Chen J., Rust N., van der Bruggen P., Cerundolo V., Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood, 10.1016/s0960-9822(98)70161-7
  73. Romero Pedro, Rod Dunbar P., Valmori Danila, Pittet Mikaël, Ogg Graham S., Rimoldi Donata, Chen Ji-Li, Liénard Danielle, Cerottini Jean-Charles, Cerundolo Vincenzo, Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes, 10.1084/jem.188.9.1641
  74. Davis Mark M., Lee Peter P., Yee Cassian, Savage Peter A., Fong Lawrence, Brockstedt Dirk, Weber Jeffrey S., Johnson Denise, Swetter Susan, Thompson John, Greenberg Philip D., Roederer Mario, 10.1038/9525